biostudies-literatureUnknown66(10)Battella SONLUS Sant'AndreaAssociazione Italiana per la Ricerca sul CancroMinistero dell’Istruzione, dell’Università e della RicercaThe importance of T cell-dependent immune responses in achieving long-term cure of chemoimmunotherapy-treated cancer patients is underscored by the recently described "vaccinal effect" exerted by therapeutic mAbs. In accordance, pre- and post-therapy peripheral blood lymphopenia represents a well-established negative prognostic factor in DLBCL. We analyzed the phenotypic and functional (IFNγ production, and Granzyme B (GrzB) cytotoxic granule marker expression) profile of peripheral blood T lymphocyte subsets ("conventional" CD4⁺ and CD8⁺, FOXP3⁺CD25^bright Treg, and "innate-like" CD56⁺) in DLBCL patients at diagnosis, and assessed the long-term impact of R-CHOP chemoimmunotherapy, in a prospective study. At diagnosis, DLBCL patients shCancer immunology, immunotherapy : CII1295-1306https://www.ebi.ac.uk/biostudies/studies/S-EPMC11028700biostudies-literaturePeripheral blood T cell alterations in newly diagnosed diffuse large B cell lymphoma patients and their long-term dynamics upon rituximab-based chemoimmunotherapy.PMC11028700Porzia AFranchitti LPalmieri GLa Scaleia RSantoni ADi Landro FMainiero FRuco LBattella SDi Napoli ACox MCMonarca BfalsePeripheral blood T cell alterations in newly diagnosed diffuse large B cell lymphoma patients and their long-term dynamics upon rituximab-based chemoimmunotherapy.The importance of T cell-dependent immune responses in achieving long-term cure of chemoimmunotherapy-treated cancer patients is underscored by the recently described "vaccinal effect" exerted by therapeutic mAbs. In accordance, pre- and post-therapy peripheral blood lymphopenia represents a well-established negative prognostic factor in DLBCL. We analyzed the phenotypic and functional (IFNγ production, and Granzyme B (GrzB) cytotoxic granule marker expression) profile of peripheral blood T lymphocyte subsets ("conventional" CD4⁺ and CD8⁺, FOXP3⁺CD25^bright Treg, and "innate-like" CD56⁺) in DLBCL patients at diagnosis, and assessed the long-term impact of R-CHOP chemoimmunotherapy, in a prospective study. At diagnosis, DLBCL patients sh2017-01-01T00:00:00Z2017 Oct2025-04-22T20:42:36.369Z2025-04-06T03:17:17.819ZS-EPMC110287002855525810.1007/s00262-017-2026-7